In its latest attempt to build market credibility, China on Monday launched the Science and Technology Innovation Board, or "STAR Market," on which 25 companies were listed.China Economyread more
Stocks in Asia traded lower on Monday morning, as a Nasdaq-style technology board on the Shanghai Stock Exchange marked its debut.Asia Marketsread more
These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
When Cathy Hsu and Tony Hsieh wanted to build an English language app for Chinese children, they decided to follow Facebook and Google's lead.Start-upsread more
Tariffs are the only instrument left for addressing China's systematic and excessive surpluses on its U.S. trades, writes Michael Ivanovitch.US Economyread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Last week shows that oil prices are not the indicator for Middle East tensions they once were, and worries about global demand and growing U.S. production has changed that...Market Insiderread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
Both drugmakers have approached Biogen regarding a possible deal, The Wall Street Journal reported, citing people familiar with the matter.
The paper said those sources said the discussions were informal and preliminary, and they may not result in a deal — in part because Biogen may not be interested. However, a source told CNBC that Allergan is unlikely to pursue the deal.
In mid-July, CEO George Scangos said he would leave Biogen in the coming months, once his replacement was found. That news sparked speculation that Scangos' departure could be a trigger for the biotech to be acquired.
"Obviously I can't comment on that," Scangos told CNBC on July 21. "That wouldn't make any logical sense to me that because I'm leaving, the company is in play. We all believe, the board believes, I believe, the future is bright for Biogen."
Scangos had been at Biogen for the past six years. In May, the company announced plans to spin off its hemophilia business, and it is in the midst of restructuring program, begun last October to cut costs and narrow its focus on core areas.
When contacted by CNBC, Biogen had no comment.
Merck spokeswoman Lainie Keller said, "We don't comment on speculation."
Allergan spokesman Mark Marmur also declined comment, saying, "Allergan does not comment on market rumor or speculation."
BIIB 2016 Stock
— CNBC's Meg Tirrell contributed to this report.